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An association between the R990G polymorphism of the
CaSR gene, coding for calcium-sensing receptor, and primary
hypercalciuria was found in kidney stone formers. To confirm
this relationship, we investigated hypercalciuric women
without stones and studied the effect of CaSR gene in human
embryonic kidney cells (HEK-293). We genotyped for CaSR
A986S, R990G, and Q1011E polymorphisms, 119
normocalciuric and 124 hypercalciuric women with negative
history of kidney stones. Homozygous (n¼ 2) or
heterozygous (n¼ 21) women for the 990G allele considered
as one group had an increased risk to be hypercalciuric (odds
ratio¼ 5.2; P¼ 0.001) and higher calcium excretion
(P¼ 0.005) in comparison with homozygous women for the
990R allele (n¼ 220). HEK-293 cells were transfected with the
variant allele at the three CaSR gene polymorphisms and with
the most common allele with no variants. The transient
increment of intracellular calcium caused by the stepwise
increase of extracellular calcium was evaluated in stable
transfected cells loaded with fura-2 AM. The extracellular
calcium concentration producing the half-maximal
intracellular calcium response was lower in HEK-293 cells
transfected with the 990G allele than in those transfected
with the wild-type allele (P¼ 0.0001). Our findings indicate
that R990G polymorphism results in a gain-of-function of the
calcium-sensing receptor and increased susceptibility to
primary hypercalciuria.
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The calcium-sensing receptor (CaSR) is a G-protein-coupled
membrane receptor that allows parathyroid and kidney
tubular cells to regulate parathyroid hormone (PTH)
secretion and tubular calcium reabsorption according to
the plasma calcium concentration.1–3 The CaSR molecule
comprises a large extracellular domain, a transmembrane
domain, and an intracellular tail.3 Calcium binding to the
extracellular domain stimulates the interaction of transmem-
brane and intracellular domains with G-proteins and
activates a complex network of intracellular messengers,
leading to phospholipase C-dependent inositol 1,4,5-tripho-
sphate production and thus calcium release from intracellular
stores as self-maintained low-frequency repetitive calcium
spikes.4,5 Through this cascade of events, CaSR activation
inhibits PTH secretion and calcium reabsorption in the thick
ascending limb.6,7 Thus, CaSR activation increases urinary
calcium excretion by both a direct and a PTH-mediated effect
on kidney tubular cells. In cultured dog kidney distal tubular
cells, CaSR inhibits active calcium reabsorption through an
inhibition of calcium pump.8 It also inhibits passive calcium
reabsorption in the thick ascending limb, where it decreases
sodium–chloride–potassium cotransport activity and, thus,
the lumen-interstitium electric potential driving passive
paracellular calcium reabsorption.7,9 In addition to para-
thyroid and kidney cells, CaSR is also expressed in many
other calcium-handling cells, such as osteoblasts and
enterocytes.10,11 However, the contribution of CaSR to the
regulation of bone remodeling and intestinal calcium
absorption still remains unclear.
In agreement with these findings, high urinary calcium
excretion and hypocalcemia characterize the phenotype of
individuals bearing activating mutations of the CaSR gene,12
whereas hypocalciuria and hypercalcemia characterize pa-
tients with CaSR-inactivating mutations.13 Three single
nucleotide polymorphisms (SNPs) of CaSR gene have been
mapped on the portion of exon 7 coding for the CaSR
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intracellular tail. In Caucasians, Ala986Ser (A986S, base
change 2956G4T) is the most frequent among these SNPs.
The 986S variant allele was associated with higher plasma
calcium concentrations, although within the normal
range.14,15 High plasma calcium concentrations have also
been reported in patients with the less-frequent SNP
Gln1011Glu (Q1011E, base change 3031C4G).15 On the
contrary, the Arg990Gly SNP (R990G, base change
2968A4G) was associated with primary hypercalciuria, as
the 990G variant allele was more frequent in hypercalciuric
calcium stone-forming patients, compared with normocal-
ciuric stone formers or healthy individuals.16 Furthermore,
the 990G variant allele was associated with slightly lower
plasma concentrations of ionized calcium in healthy
individuals15 and with lower levels of circulating PTH in
patients with primary or secondary hyperparathyroidism.17,18
Primary hypercalciuria is characterized by high calcium
excretion in the presence of normal plasma calcium
concentrations.19 The prevalence of primary hypercalciuria
is approximately 10% in the general population, whereas it is
40–50% among calcium kidney stone formers19 and approxi-
mately 20% among osteoporotic women.20 The family
clustering of primary hypercalciuria suggests that the genetic
determination of the trait is characterized by a polygenic
background.21,22 CaSR could contribute to this genetic
background and its R990G SNP increase susceptibility to
primary hypercalciuria in stone-forming patients.16 To assess
this finding in individuals without stones, the primary goal of
this work was to test the distribution of the 990G allele in
hypercalciuric women without kidney stones recruited
among women referred to the Osteoporosis Outpatient
Clinics of two Northern-Italy Hospitals. Our hypothesis
was that the 990G allele might enhance CaSR function, which
could directly inhibit calcium reabsorption in the distal
tubule. Therefore, we also tested the functional effects of the
CaSR 990G, 986S, and 1011E alleles, and of the most
common allele with no variants in human embryonic kidney
cells (HEK-293). As HEK-293 cells do not express an
endogenous CaSR, we transfected them with the CaSR gene
and compared the effect of the different alleles.23–26
RESULTS
CaSR haplotypes in hypercalciuric and normocalciuric women
Allele distribution respected Hardy–Weinberg equilibrium for
each CaSR SNP in the whole population (comparison
between expected and observed distribution: P¼ 0.99,
P¼ 0.20, and P¼ 0.91 for A986S, R990G, and Q1011E,
respectively). A986S was the most recurrent SNP in our
population. Frequency of the 990G variant allele was higher
in hypercalciuric than normocalciuric women (Figure 1a).
This finding underwent 10 000 permutations with Haploview
3.02 and remained highly significant. Linkage disequilibrium
between the investigated SNPs was very poor (Table 1).
Four haplotypes were identified in our population and
characterized by no or one single variant allele at the
investigated SNPs (Table 2). Only n¼ 5 women were double
heterozygotes at the A986S and R990G SNPs, and it was
impossible to reconstruct their haplotype because of the low
SNP frequency. Haplotype ARQ (no variant allele) was the
most frequent. Haplotype AGQ, having the 990G variant
allele, was significantly associated with hypercalciuria
(Figure 1b).
According to allele frequency, genotype distribution at the
R990G SNP was different in hypercalciuric and normocal-
ciuric women (Figure 1c). The risk to be hypercalciuric was
increased in women bearing the 990G allele compared with
the homozygous women for the 990R allele (odds ratio¼ 5.2,
95% confidence interval¼ 1.7–15.8, P¼ 0.001). Calcium
excretion was higher in heterozygous (n¼ 21;
7.2670.651 mmol/24 h) or homozygous (n¼ 2; 10.7 and
11.22 mmol per 24 h, respectively) women for the 990G allele
than homozygous women for the 990R allele (n¼ 220;
5.8270.196 mmol per 24 h; analysis of variance F¼ 5.34,
P¼ 0.005). As only two women were homozygous for the
990G allele, they were combined with heterozygous women
into one group, thus assuming the 990G allele as dominant.
Their calcium excretion was higher than in homozygous
women for the 990R allele, whereas plasma concentrations of
calcium, PTH, and 25-hydroxyvitamin D were not signifi-
cantly different (Table 3). No relationship between pheno-
types and the A986S or Q1011E SNPs was observed (Table 3).
The role of the CaSR genotypes in explaining calcium
excretion variance was tested in a stepwise multiple
regression analysis with urinary calcium excretion as the
dependent variable. Plasma concentrations of calcium,
creatinine, PTH and 25-hydroxyvitamin D, age, body weight,
and genotype at the R990G, A986S, and Q1011E SNPs were
selected as independent variables in the model. This analysis
indicated that age (r2 change¼ 0.118, F change¼ 19.5,
P¼ 0.0001) and R990G SNP (r2 change¼ 0.052, F
change¼ 9, P¼ 0.003) were associated with calcium excre-
tion (cumulative r2¼ 0.170, F¼ 14.8, P¼ 0.0001).
Functional studies in transfected HEK-293 cells
To explore the functional impact of CaSR SNPs, the
increment of intracellular calcium concentration ([Ca2þ ]i)
caused by the increase of extracellular calcium concentration
([Ca2þ ]o) was tested in HEK-293 cells transfected with the
986S, 990G, or 1011E allele or with the wild-type allele (no
variants at the three explored SNPs) or with empty plasmid
(defined as HEK-986S, HEK-990G, HEK-1011E, HEK-wt,
and HEK-vector cells, respectively) and loaded with fura-2
AM. The effective [Ca2þ ]o giving one-half of the maximal
response (EC50) value was calculated in each individual
experiments. Figure 2 shows one experiment performed on
HEK-wt and HEK-990G cells. The 990G allele determined an
increase in CaSR response to [Ca2þ ]o (Figure 3). EC50 value
was lower in HEK-990G (2.6970.11 mmol/l, n¼ 19) than in
HEK-wt cells (4.4970.15 mmol/l, n¼ 12; P¼ 0.0001; one-
way analysis of variance with Scheffe` test), HEK-986S cells
(4.2870.25 mmol/l, n¼ 11; P¼ 0.001) or HEK-1011Glu cells
(4.0470.25 mmol/l, n¼ 9; P¼ 0.001). EC50 value was not
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different in HEK-wt, HEK-986S, and HEK-1011E cells. Intact
HEK-293 cells or cells transfected with empty plasmid
showed no [Ca2þ ]i alteration at any tested Ca
2þ concentra-
tion (Figure 3).
CaSR expression in transfected HEK-293 cells
To test if the selected clones expressed the same level of CaSR,
we performed Western blot analysis. CaSR expression was
tested on immunoblots stained with anti-human CaSR
monoclonal antibody to detect total CaSR-immunoreactive
species in transfected HEK-293 cells. Under reducing
condition, the antibody detected three major bands of
250 kDa (dimeric form), 130 kDa (monomeric receptor),
and 150 kDa (glycosylated monomeric receptor).27,28 All
transfected cells showed comparable immunoreactive CaSR
expression, whereas HEK-vector cells did not show any band
(Figure 4).
Prediction of CaSR secondary structure
The protein structure prediction server method predicted
that substitution of arginine with glycine in the CaSR amino-
acid sequence at position 990 caused a break in the a-helix
between codons 984 and 997, thus substantially modifying
the secondary structure of the CaSR intracellular tail.
Prediction confidence provided by the method was between
50 and 75%.29
DISCUSSION
In a previous paper from our group, we found that the
R990G SNP of the CaSR gene was associated with primary
hypercalciuria in stone-forming patients.16 We now confirm
that the 990G allele is associated with primary hypercalciuria
in women without kidney stones, in agreement with in vitro
findings showing that the 990G allele results in a CaSR gain
of function. The association between the R990G SNP and
hypercalciuria appeared independent from kidney stone
disease, although a strong relationship between calcium
excretion and predisposition to stone production is acknowl-
edged.30 We analyzed the in vitro CaSR activity in transfected
HEK-293 cells as the capability to release calcium ions from
intracellular stores in response to an increase in extracellular
calcium concentration, a pathway dependent on phospholi-
pase C activation and inositol 1,4,5-triphosphate produc-
tion.3,4 EC50 values of CaSR activity in HEK-293 cells
transfected with the 990G allele suggested a weaker gain of
function, compared with the most activating mutations that
can produce EC50 values up to 1 mmol/l.
31 The EC50 values
that we observed in HEK-293 cells transfected with the wild-
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Figure 1 | (a) Distribution of variant alleles in hypercalciuric
(n¼ 124) and normocalciuric women (n¼ 119). The 990G allele
was more frequent in hypercalciuric than normocalciuric women. The
distribution of the other variant alleles was not different in the two
populations. Allele frequency is indicated at the top of the columns.
(b) Frequency of four haplotypes in hypercalciuric and normocalciuric
women. Haplotypes are explained in Table 1. Risk to be hypercalciuric
was increased in women bearing haplotype GGC (characterized by
variant allele only at the R990G SNP) and was calculated by logistic
regression with haplotype GAC (women with no variant alleles) as
reference group. Frequency of haplotype is indicated at the summit
of each column. (c) Distribution of genotype at the R990G SNP in
normocalciuric and hypercalciuric women. The distribution was
different in hypercalciuric and normocalciuric women with an
increased risk to be hypercalciuric in homozygotes or heterozygotes
for the rarer 990G allele (n¼ 23) compared with the homozygous
women for the 990R allele (n¼ 220).
Table 1 | Linkage disequilibrium between the SNPs located on CaSR exon 7 was computed by Haploview 3.32
Locus 1 Locus 2 D0 LOD score r2 95% CI
A986S R990G 1 0.56 0.011 0.09–0.98
A986S Q1011E 1 1.06 0.006 0.16–1
R990G Q1011E 1 0.3 0.001 0.06–0.98
No significant linkage was found.
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Table 2 | Four different haplotypes were defined
Base change in codon Amino-acid change
Haplotype Haplotype feature 986 990 1011 986 990 1011
ARQ No variant allele GCC AGG CAG A R Q
SRQ Variant allele at the A986S SNP TCC AGG CAG S R Q
AGQ Variant allele at the R990G SNP GCC GGG CAG A G Q
ARE Variant allele at the Q1011E SNP GCC AGG GAG A R E
Haplotype ARQ is the most frequent haplotype and may be considered as the ‘wild-type’ sequence (no variant allele at studied SNPs). SRQ, AGQ, and ARE were characterized
by the presence of one variant allele at the A986S, R990G, and Q1011E SNPs, respectively. Only five women were double heterozygotes at the A986S and R990G SNPs. These
women were excluded from the haplotype analysis, because their haplotype could not be reconstructed due to low frequency of each SNP in the population sample.
Haplotypes were identified by the aminoacid coded at the three studied polymorphic loci. Base and aminoacid changes are displayed for each SNP.
Table 3 | Mean values (7s.e.) of the measured variables in women divided according to their genotype
A986S R990G Q1011E
Homozygotes
986A
Heterozygotes and
homozygotes 986S
Homozygotes
990R
Heterozygotes and
homozygotes 990G
Homozygotes
1011Q
Heterozygotes
1011E
N 168 75 220 23 230 13
Age (years) 6270.7 6071.3 6170.7 6371.8 6270.7 6172.7
Body weight (kg) 6170.8 6071.0 6170.7 6171.9 6170.6 6273.0
Plasma creatinine (mg/dl) 0.7770.011 0.7470.018 0.7670.01 0.7670.028 0.7670.01 0.7770.029
Plasma calcium (mmol/l) 2.4070.009 2.4270.013 2.4170.008 2.3870.020 2.4170.008 2.4370.038
Plasma iPTH (pg/ml) 4771.5 5072.3 4871.4 4873.8 4871.3 5075.7
Plasma 25(OH)D3 (ng/ml) 3172.5 2973.4 2972.2 3475.8 3072.1 1975.4
Urinary calcium (mmol/24 h) 6.0170.233 5.7270.323 5.8270.196 7.5970.63a 6.0370.193 5.2070.966
As the number of homozygous individuals for variant allele at the A986S and R990G SNPs was small, they were analyzed as unique groups with the heterozygotes, assuming
the dominant model of analysis. No homozygous women for variant allele at the Q1011E SNP were detected.
aP=0.006 (Student’s t-test).
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Figure 2 | [Ca2þ ]o-evoked increases in [Ca
2þ ]i in HEK-293 cells
transfected with the CaSR wild type (HEK-wt cells), or the 990G
allele (HEK-990G cells), or empty vector (HEK-vector cells),
loaded with fura-2 AM. At each arrow, the concentration of [Ca2þ ]o
was increased by adding a small volume of a CaCl2 stock solution to
the bath solution. The gray double arrows indicate the peak of
[Ca2þ ]i response after the individual [Ca
2þ ]o stimulus in cells.
23 The
lower panel displays the tested concentrations of [Ca2þ ]o in the assay
medium.
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Figure 3 | Normalized transient [Ca2þ ]i response to stepwise
[Ca2þ ]o increase. HEK-293 cells transfected with CaSR wild type,
986S, 990G, 1011E, or empty vector were loaded with fura-2 AM. Error
bar represents s.e. The transient [Ca2þ ]i response to the [Ca
2þ ]o
increase is plotted against the concentration of [Ca2þ ]o. Transient
response was normalized to the maximal cumulative response of the
CaSR. EC50 [Ca
2þ ]o value in HEK-990G cells (2.6970.11; n¼ 19) was
significantly lower than in HEK-wt (4.4970.15; n¼ 12; P¼ 0.0001,
analysis of variance with Sheffe` test)), HEK-986S (4.2870.25; n¼ 11;
P¼ 0.0001), and HEK-1011E cells (4.0470.25; n¼ 9; P¼ 0.0001). EC50
[Ca2þ ]o value was not different in HEK-wt, HEK-986S, and HEK-1011E
cells.
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type allele was in the range of 3–4.5 mmol/l, commonly
reported by other authors.3,12,13,31
The association of higher calcium excretion with the 990G
allele was observed in patients with primary hyperparathyr-
oidism, where a correlation of this allele with kidney stones
was also reported, confirming the role of excreted calcium in
stones formation.17,30,32 Before the present study, the only
article on functional effects of exon 7 SNPs did not find any
change in CaSR activity in HEK-293 cells transfected for the
990G allele.33 Different experimental procedures might
explain this discrepancy; however, how experimental differ-
ences may impact CaSR activity remains unexplained.
An activated CaSR response to extracellular calcium may
predispose to hypercalciuria through a greater inhibition of
calcium reabsorption in the ascending limb cells in which
CaSR is expressed on basolateral plasma membrane.7 The
relative rarity of the 990G variant allele agrees well with the
low frequency of hypercalciuria of renal origin. However,
renal hypercalciuria has been mainly studied in stone-
forming patients34 as few studies have analyzed hypercalciur-
ia determinants in stone-free individuals.35 CaSR is also
expressed in enterocytes and osteoblasts and changes of
activity in hypercalciuria are likely to affect calcium
metabolism also in bones and intestine, although we can
only assess the effect of those changes in the kidney.10,11 No
other causes of hypercalciuria were evident in women bearing
the 990G allele. In particular, vitamin D stores were not
different in women with different genotype and were not
related to vitamin D supplementation or with plasma
concentrations of calcium or PTH.
In women bearing the 990G variant allele, the increase in
calcium excretion was not coupled with a decrease in plasma
concentrations of calcium and PTH. Accordingly, previous
works reported a significant decrease only in plasma-ionized
calcium concentrations, which were not measured in our
patients.15 In studies in patients with primary hyperpar-
athyroidism and in uremic patients with secondary hyper-
parathyroidism, lower plasma PTH concentrations were
instead associated with the 990G allele.17,18 The lack of a
clear association between the CaSR 990G allele and PTH
production or plasma calcium concentration, suggests that
this allele could influence PTH secretion less markedly than
tubular calcium reabsorption, or that other variables, like
intestinal calcium absorption and dietary calcium intake,
may limit the effect of 990G on PTH secretion and
circulating calcium.
The neutral amino-acid glycine substituting the basic
amino-acid arginine at residue 990, changes the local electric
charge distribution on intracellular domain of CaSR. More-
over, glycine allows a wider rotation angle of the a-helix in
the protein secondary structure than amino acids with longer
lateral chains as arginine.36 Therefore, it is likely that glycine
990 changes the spatial conformation and folding of the
CaSR intracellular domain, altering the capability of CaSR to
activate G proteins or to bind filamin-A. The adopted Jones’
model indicated that glycine 990 causes a break in the a-
helix.29 The spatial modification of CaSR intracellular tail
may modify its efficiency in activating G protein and, thus,
phospholipase C, A, or D.37 These intracellular signaling
pathways seem differently involved in the regulation of
parathyroid secretion or kidney calcium reabsorption. CaSR-
stimulated phospholipase C activity inhibits PTH secretion
through inositol-1,4,5-triphosphate production and calcium
mobilization from intracellular stores. Stimulation of phos-
pholipase A to produce 20-hydroxyeicosatetraenoic acid
inhibits sodium and calcium reabsorption in thick ascending
limb of the Henle loop.7,39 Because it is expressed in
intracellular tail, the R990G SNP might activate phospholi-
pase A or C to a different degree, thus influencing PTH
secretion less markedly than tubular calcium reabsorption.4,7
This different degree of activation of phospholipase A or C
could explain the lack of hypocalcemia in individuals bearing
the 990G allele. The intracellular tail also interacts with
filamin-A, a protein anchoring CaSR to caveolae in
parathyroid cells and functioning as a scaffolding protein to
maintain signaling activity of CaSR at an optimal level.38 The
binding site of CaSR to filamin A includes the amino acids
between positions 907 and 997, thus comprising residue
990.38 In conclusion, a conformational change caused by the
R990G SNP in the intracellular domain may be responsible of
a CaSR gain of function that modulates CaSR interaction
with G proteins or filamin A, increasing individual suscept-
ibility to primary hypercalciuria.
MATERIALS AND METHODS
Patients
One hundred and nineteen normocalciuric (age¼ 6371.0 years,
body weight¼ 6270.9 kg, urinary calcium excretion¼ 3.457
0.122 mmol per 24 h) and 124 hypercalciuric women (age¼ 6070.8
-Actin
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986S
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990G
HEK-
1011E
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Figure 4 | Immunoblot of CaSR in HEK-wt, HEK-986, HEK-990G,
and HEK-vector cells. Total proteins were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to
nitrocellulose filter. After incubation with antihuman CaSR
monoclonal antibody, filters were developed with enhanced
chemiluminescence as described in the Material and Methods
section. Upper panel shows three major bands of 250 kDa (dimeric
form), 130 kDa (monomeric receptor), and 150 kDa (glycosylated
monomeric receptor). The same membrane was also incubated with
anti-b-actin polyclonal antibody, as housekeeping expression control
(lower panel).
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years, body weight¼ 6070.9 kg, urinary calcium excre-
tion¼ 8.4370.161 mmol per 24 h) were recruited among patients
referred to the Outpatient Osteoporosis Clinics at the San Raffaele
Hospital in Milan (n¼ 213, 98 hypercalciuric and 115 normocal-
ciuric women) and from Policlinico Hospital in Padua (n¼ 30, 26
hypercalciuric and four normocalciuric women). Participants were
defined as hypercalciuric when their 24-h calcium excretion was
46.25 mmol, or 40.1 mmol/kg of body weight. They were
genotyped for three SNPs within exon 7 of the CaSR gene.
Women were eligible for the study if they were Caucasian, had no
personal history of kidney stones, and had normal plasma creatinine
and calcium concentrations. Women were included regardless of
their bone mineral density values, none had diseases other than
osteoporosis. No participants have been taking antifracture drugs or
drugs affecting calcium excretion (thiazide, bisphosphonate, vitamin
D, calcium, or others) in the 3 months preceding their inclusion in
the study. Plasma concentrations of calcium and creatinine and 24-h
urinary calcium excretion were measured in all participants using
standard methods. Serum intact PTH was measured by immunor-
adiometric assays (Nichols Institute Diagnostics, San Juan Capis-
trano, CA, USA). Plasma 25-hydroxyvitamin D was measured by
radioimmunoassay method (Diasorin, Stillwater, MN, USA).
The study complies with the Declaration of Helsinki Principles
and was approved by the San Raffaele Hospital Ethical Committee.
All participants signed an informed consent, which included consent
for genetic testing.
Genotyping
Genomic DNA was isolated from peripheral blood cells by standard
procedures. The part of exon 7 of CaSR gene, comprising three
nonconservative SNPs (G/T at codon 986, A/G at codon 990 and
C/G at codon 1011), was evaluated by polymerase chain reaction
amplification and direct sequencing. Polymerase chain reaction was
carried out using primers 50-CAGAAGGTCATCTTTGGCAGCGG
CA-30 and 50-TGCAGACCTGTTTCCTGGACGGTC-30, as described
previously.16
Site-directed mutagenesis of the human CaSR and stable
receptor expression
The human CaSR cDNA, cloned in pCR3.1 plasmid (Invitrogen,
Carlsbad, CA, USA), was kindly provided by Dr Jianxin Hu (NIH,
Bethesda, MD, USA). The plasmid checked by sequencing was found
to bear the 990G allele (haplotype AGQ). Separate point mutations
were performed to produce CaSR containing 986S, 990R, or 1011E
allele, respectively. Site-directed mutagenesis was directly performed
on CaSR-plasmid using Gene Tailor Mutagenesis System (Invitro-
gen), according to the manufacturer’s instructions. The mutations
were produced by polymerase chain reaction amplification using a
couple of overlapping primers for each mutant, only one containing
the target mutation site (Table 4). The Platinum Taq DNA
Polymerase High Fidelity (Invitrogen) was used for 20 cycles
amplification, according to Gene Tailor Mutagenesis System
procedure. Mutant plasmids were amplified in Escherichia coli,
DH-5a strain, and DNA was extracted with the alkaline lysis
procedure. The sequence of mutant receptor was confirmed by
automated DNA sequencing of entire CaSR complementary DNA
on ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, CA,
USA).
Human embryonic kidney cells (HEK-293; Cell Bank, IST,
Genoa, Italy) were grown in Dulbecco’s modified Eagle’s medium
(Sigma Chemicals, St Louis, MO, USA), supplemented with 10%
fetal bovine serum and 1% penicillin/streptomycin under standard
condition (5% CO2, 371C). Each 75 cm
2 flask of 80–90% confluent
HEK-293 cells were transfected with 24 mg plasmid DNA, using
LipofectAMINE 2000 (Invitrogen).
Stable clone selection began 48 h after the start of transfection in
medium with 1 mg/ml geneticin (Sigma Chemicals). The clones
were available in 1–2 weeks and cultured routinely. Resistant
colonies were subcloned and screened for CaSR expression with
Western blot analysis. The selected clones (HEK-wt, HEK-990G,
HEK-986S and HEK-1011E cells) expressed similar levels of CaSR
protein, whereas no expression was found in cells transfected with
empty plasmid (HEK-vector; Figure 4).
Western blotting
Stable transfected cells were trypsinized and the pellet was lysed with
ice-cold lysis buffer (150 mmol/l NaCl, 10 mmol/l Tris–HCl pH 7.2,
0.1% sodium dodecyl sulfate, 1% TritonX-100, 1% deoxycholate,
5 mmol/l ethylenediaminetetraacetic acid, 1 mmol/l phenylmethyl-
sulfonyl fluoride, 10 mmol/l benzamidine, 2 mg/ml leupeptin, and
0.1 mmol/l Na-orthovanadate). The extracts were forced through a
22-gauge needle 5–8 times, the lysate was centrifuged at 15 000 r.p.m.
for 10 min at 41C and the supernatant was collected and stored at
801C. Protein concentration was assayed using Bradford reagent
(Sigma Chemicals). Samples (5 mg proteins per well) were denatured
with denaturing buffer: 7 mol/l urea, 2 mol/l thiourea, 65 mmol/l
dithiothreitol, 5 laemmli sample buffer (final concentration 2%
sodium dodecyl sulfate) for 30 min at room temperature. Iodoace-
tamide (130 mmol/l) was added to block dithiothreitol for 30 min at
room temperature. Proteins were separated on 8% laemmli gel and
then electrotransferred to polyvinylidene difluoride membrane at
400 mA for 1 h. The blots were blocked in a blocking solution (5%
milk in Tris-buffered saline Tween) and then incubated for 2 h at at
room temperature with 0.2 mg/ml monoclonal anti-CaSR antibody
(average daily dose, against residues 214–235 of the human CaSR
protein (AffinityBioreagents, Golden, CO, USA)). Then, membranes
were incubated in the blocking solution with secondary horseradish
peroxidase-coupled anti-mouse IgG (Jackson ImmunoResearch
Laboratories, Suffolk, UK) at a 1:10000 dilution for 1 h at room
temperature. The same membranes were incubated with polyclonal
anti-b-actin antibody (Sigma Chemicals), overnight at 41C with a
1:1000 dilution. This primary antibody was revealed with secondary
horseradish peroxidase-coupled anti-rabbit IgG (Amersham Bio-
sciences, Little Chalfont, UK) with a 1:5000 dilution for 1 h at at
Table 4 | Primer sequences used to perform site-direct mutagenesis
Forward (mutagenic) primer Reverse primer
990Arg (wild type) 50-AAGAACGCCATGGCCCACAGGAATTCTAC-30 50-GTGGGCCATGGCGTTCTTCTGAGGCTCAT-30
986Ser 50-GAGCCTCAGAAGAACTCCATGGCCCACAGG-30 50-GTTCTTCTGAGGCTCATCAAAGCTCAGTGAGA-30
1011Glu 50-ACGCTGACCCGACACGAGCCATTACTCC-30 50-GTGTCGGGTCAGCGTATCGCTGCTTTTC-30
Modified bases are in bold.
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room temperature. Specific protein bands were detected using
SuperSignal West Pico enhanced chemiluminescence system (Pierce,
Rockford, IL, USA).
Measurement of [Ca2þ ]i
About 5 105 cells/ml of HEK-293 were used for each experiment.
Cells were suspended in a bath solution (123 mmol/l NaCl, 5 mmol/l
KCl, 1 mmol/l MgCl2, 10 mmol/l glucose, 25 mmol/l N-2-hydro-
xyethylpiperazine-N0-2-ethanesulfonic acid, 0.5 mmol/l CaCl2, pH
7.4, at 371C, 285 mOsm/l) and loaded with fura-2 AM (1mmol/l,
Sigma Chemicals), at 371C for 45 min. After incubation, cells were
washed with the bath solution and the same cell concentration was
transferred into a thermostatted quartz cuvette containing the bath
solution. [Ca2þ ]o was increased stepwise by adding CaCl2 to the
bath solution to reach calcium concentration of 0.9, 1.5, 2.3, 3.3, 5.3,
7.3, 9.3, and 11.3 mmol/l in the assay medium.23 The fluorescence
measurements were carried out as described previously.24,25
Transient responses of [Ca2þ ]i were normalized according to Pearce
et al.23 Briefly, the size of the peak of the transient [Ca2þ ]i in
response to each tested [Ca2þ ]o stimulus was summed to the size of
the previous individual peaks and expressed as the proportion of the
total peak counts for the full concentration–response curve. EC50
value was calculated in each individual experiments.
CaSR secondary-structure prediction
The correlation between CaSR secondary structure type and the
substitution of arginine with glycine at the position 990 was
predicted according to the Jones’ criteria.34 We applied the
prediction method PSIPRED (protein structure prediction server)
for protein sequence analysis,29 available on server ‘Predict Protein’
(http://cubic.bioc.columbia.edu/ predictprotein/).
Statistical analysis
Distribution of CaSR alleles, haplotypes, or genotypes was compared
in normocalciuric and hypercalciuric women by w2 test or multi-
variable logistic regression. Relative risk to be hypercalciuric was
estimated by calculating the odds ratio and 95% confidence interval.
Quantitative variables were reported as mean7s.e. Differences
between means were tested by Student’s t-test or one-way analysis of
variance. Sheffe` post hoc test was used to compare results in
transfected cells. Dependence of calcium excretion on CaSR
genotypes was evaluated by stepwise multiple regression analysis.
Statistical analysis was performed using the SPSS 10 statistical
package. Linkage disequilibrium between SNPs was tested measur-
ing D0 and LOD score using Haploview 3.32 software (http://
www.broad.mit.edu/mpg/haploview/).40 The same software was
adopted for haplotype reconstruction and to submit allele distribu-
tion findings to permutation procedure (number of per-
mutations¼ 10 000).
As our primary goal was to test the association of the R990G SNP
with hypercalciuria, statistical analysis was conducted at the a¼ 0.05
level and was two-tailed. For this a level, the power to test the
association of allele at the R990G SNP with hypercalciuria was
calculated with the ‘PAWE’ software (http://linkage.rockefeller.edu/
pawe/pawe.cgi) and was 92.3%.41
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